News Articles - Triumvira Immunologics | Engineered T Cell Therapies

February 6, 2024

Triumvira Immunologics Pivots to Claudin 18.2-Targeted Cell Therapy, Pauses HER2 Program

January 12, 2024

JPM2024: On the Ground in San Francisco

January 10, 2024

Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors

FDA’s CAR T Probe ‘Not a Big Deal’ for Oncology-Focused Biotechs: Triumvira President

January 4, 2024

Alternative Funding Strategies to Discuss at JPM

December 15, 2023

What Do You See As The Most Significant Regulatory Decision Or Guidance On The Horizon For 2024 (Or Beyond)?